Tula hantavirus isolate with the full-length ORF for nonstructural protein NSs survives for more consequent passages in interferon-competent cells than the isolate having truncated NSs ORF

Virology Journal
Kirsi Maria JääskeläinenA Plyusnin

Abstract

The competitiveness of two Tula hantavirus (TULV) isolates, TULV/Lodz and TULV/Moravia, was evaluated in interferon (IFN) -competent and IFN-deficient cells. The two isolates differ in the length of the open reading frame (ORF) encoding the nonstructural protein NSs, which has previously been shown to inhibit IFN response in infected cells. In IFN-deficient Vero E6 cells both TULV isolates survived equally well. In contrast, in IFN-competent MRC5 cells TULV/Lodz isolate, that possesses the NSs ORF for the full-length protein of 90 aa, survived for more consequent passages than TULV/Moravia isolate, which contains the ORF for truncated NSs protein (66-67 aa). Our data show that expression of a full-length NSs protein is beneficial for the virus survival and competitiveness in IFN-competent cells and not essential in IFN-deficient cells. These results suggest that the N-terminal aa residues are important for the full activity of the NSs protein.

References

Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M O DiazJ D Rowley
Jun 1, 2002·Archives of Virology·A Plyusnin
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Erika GeimonenErich R Mackow
Jan 15, 2003·Journal of Virology·D F YoungR E Randall
May 20, 2004·The Journal of Biological Chemistry·Daniel ThomasFriedemann Weber
Nov 17, 2005·Journal of Neurovirology·Samantha S Soldan, Francisco González-Scarano
Mar 1, 2006·Journal of Virological Methods·Andreas RangDetlev H Krüger
May 13, 2006·Science·Adolfo García-Sastre, Christine A Biron
Jun 15, 2007·Journal of Bacteriology·Marco CandelaPatrizia Brigidi
Aug 21, 2007·Journal of Medical Virology·Kirsi M JääskeläinenAlexander Plyusnin

❮ Previous
Next ❯

Citations

Dec 4, 2009·Archives of Virology·Jussi Oskari VirtanenAlexander Plyusnin
Apr 9, 2010·Clinical Microbiology Reviews·Colleen B JonssonOlli Vapalahti
Nov 6, 2009·Journal of Virology·Jonas Schmidt-ChanasitRainer G Ulrich
Mar 4, 2011·Journal of Virology·Valery MatthysErich R Mackow
Dec 14, 2011·Journal of Virology·Jorge Vera-OtarolaMarcelo López-Lastra
Dec 2, 2008·PLoS Pathogens·Judith D Easterbrook, Sabra L Klein
Aug 28, 2012·Advances in Virology·Valery Matthys, Erich R Mackow
Feb 3, 2016·Archives of Virology·Sabrina SchmidtRainer G Ulrich
Nov 26, 2008·Cytokine & Growth Factor Reviews·Friedemann Weber, Ali Mirazimi
Oct 8, 2008·Immunological Reviews·Günther SchönrichRainer G Ulrich
May 25, 2012·The Journal of General Virology·Jussi HepojokiAntti Vaheri
May 24, 2016·Viruses·Amelina AlbornozNicole D Tischler
Dec 1, 2009·Viruses·Richard M Elliott, Friedemann Weber
Dec 22, 2010·Expert Review of Anti-infective Therapy·Jonas Klingström, Clas Ahlm
Nov 22, 2017·Virus Genes·Monika Reuter, Detlev H Krüger
Apr 24, 2020·Journal of Virology·Jorge Vera-OtarolaMarcelo López-Lastra

❮ Previous
Next ❯

Methods Mentioned

BETA
in vitro transcription
PCR

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.